用于分期前列腺癌的全身MRI：叙事评论
Whole-body MRI for staging prostate cancer: a narrative review
影响因子:4.40000
分区:医学2区 / 泌尿学与肾脏学2区
发表日期:2025 Jan
作者:
Andrew M Fang, Justin R Gregg, Curtis Pettaway, Jingfei Ma, Janio Szklaruk, Tharakeswara K Bathala, Devaki Shilpa S Surasi, Brian F Chapin
摘要
To present a narrative review regarding the diagnostic accuracy of whole-body magnetic resonance imaging (WBMRI) in staging patients with high-risk prostate cancer (HRPCa) and compare it to established imaging modalities.A narrative review was carried out using PubMed using the following keywords: 'whole body', 'magnetic resonance imaging', 'MRI', 'prostate cancer', 'risk stratification', and 'staging'.包括评估WBMRI作为对HRPCA的舞台患者的成像方式的文章，而仅评估生化复发或转移性疾病进展的研究被排除在淋巴转移酶的评估中，WBMRI的评估是可比较的，即使不适当的，如果没有改善，敏感性和特定性与常规图像concoption of Concomental Impography相比，则证明是可比的。此外，与骨闪烁显像（BS）相比，WBMRI在检测骨转移方面表现出提高的敏感性和特异性。然而，随着前列腺特异性膜抗原（PSMA）放射性术的出现，用于正电子发射断层扫描（PET），WBMRI检测转移性疾病的诊断性能似乎不优于WBMRI的诊断能力。但是，WBMRI的性能不如PSMA PET/CT。需要进一步研究WBMRI和PSMA PET/CT之间的成本比较，并且需要评估PSMA PET/MRI合并的评估。
Abstract
To present a narrative review regarding the diagnostic accuracy of whole-body magnetic resonance imaging (WBMRI) in staging patients with high-risk prostate cancer (HRPCa) and compare it to established imaging modalities.A narrative review was carried out using PubMed using the following keywords: 'whole body', 'magnetic resonance imaging', 'MRI', 'prostate cancer', 'risk stratification', and 'staging'. Articles that evaluated WBMRI as the imaging modality to stage patients with HRPCa were included, while studies that solely assessed for biochemical recurrence or metastatic disease progression were excluded.In the evaluation of lymphatic metastases, WBMRI has demonstrated a comparable, if not improved, sensitivity and specificity compared to conventional imaging of computed tomography (CT). Furthermore, WBMRI demonstrates improved sensitivity and specificity in detecting bone metastases compared to bone scintigraphy (BS). However, with advent of prostate-specific membrane antigen (PSMA) radioligands for positron emission tomography (PET), the diagnostic performance of WBMRI to detect metastatic disease appears inferior.The diagnostic capabilities of WBMRI exceed that of conventional imaging of CT and BS in detecting metastatic disease in patients with HRPCa. However, WBMRI does not perform as well as PSMA PET/CT. Further study on cost comparisons between WBMRI and PSMA PET/CT are needed, as well as evaluations of combined PSMA PET/MRI are needed.